In his latest essay, Charles Kenny seeks to revive Solow's model of exogenous growth; growth driven by the global diffusion of new technologies and ideas. He suggests that when it comes to quality of life improvements, institutions may be less important than exogenous factors, like new vaccines, oral re-hydration therapies, or improvements in hygiene and education practices.
Charles Kenny attempts to dispel development pessimists' fears in this essay summarizing his latest book Getting Better: Why Global Development Is Succeeding - And How We can Improve the World Even More (Basic Books). According to Charles, better health, education, greater access to civil and political rights, infrastructure and even beer, are all signs historic progress being made in the developing world.
Food Crisis, Household Welfare, and HIV/AIDS Treatment: Evidence from Mozambique - Working Paper 238
Using panel data from Mozambique collected in 2007 and 2008, the authors explore the impact of the food crisis on the welfare of households living with HIV/AIDS. While HIV households have not suffered more from the crisis than others, infected people who experienced a negative income shock also expereinced a reduction or a slower progression in outcomes when treating their illness.
Where Have All the Donors Gone? Scarce Donor Funding for Non-Communicable Diseases Working Paper 228
Once rich-world woes, non-communicable diseases such as diabetes and cancer account for half the burden of disease in the developing world. Yet Rachel Nugent finds that barely 3 percent of aid and philanthropic spending on health addresses this neglected health crisis.
For the past decade, global AIDS donors have responded to HIV/AIDS in sub-Saharan Africa as an emergency and have mobilized health workers from weak and understaffed workforces. They must begin to address the long-term problems underlying the shortages and the effects of their efforts on the health workforce more broadly.
This report focuses on the workforce strengthening strategies of three of the major HIV/AIDS donors—the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), and the World Bank’s Africa Multi-country HIV/AIDS Program (the MAP)—and identifies six tasks for donors, national governments, and country stakeholders to undertake to reverse the severe shortage of skilled, motivated, and productive health workers.
In this working paper, the authors introduce an MDG Progress Index to assess how on or off track countries are toward MDG targets.
Improving adolescent girls’ health and wellbeing is critical to achieving virtually all international development goals. Start with a Girl: A New Agenda for Global Health shows why doing so is a global must and identifies eight priorities for international action.
Bridging the Gap: Better, Faster, and Cheaper Clinical Trials for Health Products for Neglected Diseases - Working Paper 217
There has been tremendous progress over the last decade in the development of health products for neglected diseases, but two substantial bottlenecks threaten our capacity to bring these products to those in need.
FDA’s Role in Improving the Development Pathway for Neglected Disease Therapies - Congressional Testimony
Visiting Fellow Tom Bollyky testified before the U.S. Senate Appropriations Subcommittee on Agriculture, Rural Development, the Food and Drug Administration, and Related Agencies on how the FDA can help develop programs for neglected diseases. Programs for neglected diseases, such as tuberculosis, malaria and other parasitic illnesses, lack a regulatory infrastructure to ensure programs work properly.
The Center for Global Development’s Drug Resistance Working Group urges pharmaceutical companies, governments, donors, global health institutions, health providers, and patients to collectively and immediately tackle this global health threat by implementing four key recommendations.
In an increasingly interconnected world, drug resistance does not stop at a patient’s bedside—it threatens global health. The conclusions of the Center for Global Development’s Drug Resistance Working Group make clear the need for urgent action to address this growing crisis.
In the final installation of a three-part series, Mead Over estimates the fiscal burden of international AIDS treatment programs, and suggests ways that donors, governments, and patients can sustain current treatments while preventing future cases.
This essay proposes ways to improve the effectiveness of HIV prevention by strengthening incentives for both measurement and achievement. It builds upon a companion essay that proposes an “AIDS Transition”—that is, a gradual reduction in the number of people infected with HIV even as those inflected live longer—as a reasonable objective of donor and government AIDS policy.
Recognizing the donors’ obligation to sustain financing for the millions of AIDS patient who would not be alive today without it, this essay proposes a dynamic paradigm for the struggle with the AIDS epidemic—“the AIDS transition” —and argues that to most rapidly achieve an AIDS transition new funding of AIDS treatment should be tightly linked to dramatically improved and transparently measured prevention of HIV infections.
How to Pay “Cash-on-Delivery” for HIV Infections Averted: Two Measurement Approaches and Ten Payout Functions - Working Paper 210
This paper proposes a cash-on-delivery approach to reward AIDS programs in accordance with the number of verifiable HIV infections they avert.
Billions of dollars have been allocated to fight HIV/AIDS in poor countries over the past decade, yet less than half of those requiring treatment receive it, and for every two people put on treatment, five more become infected. Donors have to do more with available funds. Now is the time to link funding decisions to performance.
This report examines the use of performance-based funding (PBF) among the big three funders of HIV/AIDS programs in developing countries: the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS Tuberculosis and Malaria, and the World Bank’s Multi-Country HIV/AIDS Program for Africa (the MAP).